Core Viewpoint - The company, Jinhua Enterprises (Group) Co., Ltd., has announced the progress of its share repurchase and reduction plan, indicating that it has not yet executed the planned reduction of repurchased shares as of the end of December 2025 [2][3]. Group 1: Share Repurchase Details - The company repurchased a total of 20,557,582 shares from February 23, 2024, to May 22, 2024, which accounts for 5.51% of its total share capital [2]. - Out of the repurchased shares, 2,750,000 shares (0.74% of total share capital) were allocated for employee stock ownership plans or equity incentives, while 17,807,582 shares (4.77% of total share capital) were repurchased to maintain company value and protect shareholder interests [2]. Group 2: Reduction Plan Progress - The company disclosed a plan on October 30, 2025, to reduce up to 7,465,405 repurchased shares (2% of total share capital) through centralized bidding within six months following the announcement [3]. - As of November 30, 2025, the company had not yet executed any reductions of the repurchased shares, and this status remained unchanged as of December 31, 2025 [3][3]. Group 3: Compliance and Regulations - The company is required to disclose the progress of the share reduction plan within the first three trading days of each month, based on the previous month's status [5]. - The reduction plan is consistent with prior commitments made by major shareholders and does not involve any significant corporate actions such as high stock dividends or mergers during the reduction period [6][7].

证券代码：600080 证券简称：金花股份 公告编号：2026-003 金花企业（集团）股份有限公司 关于集中竞价减持已回购股份的进展公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购股份的基本情况 金花企业（集团）股份有限公司（以下简称"公司"）于 2024 年 2 月 23 日 至 2024 年 5 月 22 日期间通过集中竞价交易方式累计回购公司股份 20,557,582 股，占公司总股本的 5.51%。其中，用于员工持股计划或股权激励累计回购股份 2,750,000 股（占公司总股本 0.74%）；用于维护公司价值及股东权益累计回购股 份 17,807,582 股（占公司总股本 4.77%）。具体内容详见公司于 2024 年 5 月 22 日披露的《关于股份回购实施结果暨股份变动的公告》（公告编号：2024-037 号）。 减持计划的进展情况 2025 年 10 月 30 日，公司披露了《金花企业（集团）股份有限公司关于回 购股份集中竞价减持计划的公告》（公告编号：2025-044 号 ...

关于控股股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码：600080 股票简称：金花股份 编号：临 2026-002 金花企业（集团）股份有限公司 （二）本次股份质押不存在被用作重大资产重组业绩补偿等事项的担保或其 他保障用途。 （三）股东累计质押股份情况 上表中质押起始日为质押合同签订日，质押到期日具体以实际解除质押登记 日期为准。 | | 持股数量 | 持股 | 本次质押前 | 本次质押后 | 占其所 | 占公司 | 已质押股份情况 已质押股 | 已质押股 | 未质押股份情况 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 名称 | （股） | 比例 | 累计质押数 | 累计质押数 | 持股份 | 总股本 | | | | 未质押股 | | | | | 量（股） | 量（股） | 比例 | 比例 | 份中限售 | 份中冻结 | 中限售股份 | 份中冻结 | | | | ...

Core Viewpoint - The controlling shareholder and actual controller of Jinhua Co., Xing Boyue, has pledged 5.8 million shares, which is 6.12% of his holdings and 1.55% of the total share capital, to Wuhan Zhiyi Trading for business operations [1] Group 1 - Xing Boyue holds a total of 94.7924 million shares, representing 25.40% of the total share capital [1] - After the recent pledge, the cumulative pledged shares amount to 73.97 million, which is 78.03% of his holdings and 19.82% of the total share capital [1] - The financing balance corresponding to the pledged shares due in the next six months and one year is 23 million yuan and 250 million yuan, respectively, indicating that the pledge risk is controllable [1]

国金证券股份有限公司 关于金花企业(集团)股份有限公司 部分募投项目延期的核查意见 国金证券股份有限公司（以下简称"国金证券"）作为金花企业（集团）股 份有限公司（以下简称"公司"或者"金花股份"）非公开发行 A 股股票的保荐 机构，根据《证券发行上市保荐业务管理办法》《上市公司募集资金监管规则》 《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等有关规定的要 求，对金花股份募投项目延期的事项进行了审慎核查，并发表了独立意见，具体 情况如下： 一、募集资金基本情况 经中国证监会《关于核准金花企业（集团）股份有限公司非公开发行股票的 批复》（证监许可[2017]1648 号）核准，金花企业（集团）股份有限公司（以下 简称"公司"）发行股票 67,974,413 股（A 股），发行价格为人民币 9.38 元/股， 本次发行募集资金总额为人民币 637,599,993.94 元，扣除各项发行费用后，实际 募集资金净额为人民币 628,780,819.60 元。瑞华会计师事务所（特殊普通合伙） 已对上述募集资金的到位情况进行了审验，并于 2018 年 3 月 22 日出具的《金花 企业（集团）股份有限公司 ...

金花企业（集团）股份有限公司 关于部分募集资金投资项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担个别及连带责任。 金花企业（集团）股份有限公司 （以下简称"公司"或"金花股份"）于 2025 年 12 月 30 日召开第十届董事会第二十五次会议，审议通过了《关于部分募集资金投资项 目延期的议案》，同意公司在不改变募集资金投资项目（以下简称"募投项目"）、投资 内容、投资总额、实施主体等情况下，根据募投项目的实施进度，对部分募投项目进行 延期。公司保荐机构国金证券股份有限公司（以下简称"国金证券"或"保荐机构"） 出具了明确的核查意见。该事项无需提交公司股东会审议。现就相关事项公告如下： 一、募集资金基本情况 经中国证监会《关于核准金花企业（集团）股份有限公司非公开发行股票的批复》 （证监许可[2017]1648 号）核准，公司发行股票 67,974,413 股（A 股），发行价格为人 民币 9.38 元/股，本次发行募集资金总额为人民币 637,599,993.94 元，扣除各项发行 费用后，实际募集资金净额为人民币 6 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 来源：九州商业观察 12月17日，金花企业（集团）股份有限公司（股票简称：金花股份（维权），代码：600080）一纸公告 揭开了资本市场信息披露违规的典型案例。公司董事长邢雅江因隐瞒2024年4月至7月期间被公安机关取 保候审的关键事实，未及时履行信息披露义务，最终收到陕西证监局的行政处罚决定书——被给予警告 并处以350万元罚款，这一金额远超其2024年112.03万元的税前年薪，成为监管层严打信披违规的又一 重磅案例。 回溯事件始末，2024年4月23日，邢雅江因他人涉嫌私自刻制无关公司印章案被牵连，西安市公安局鄠 邑分局对其采取取保候审措施。同年7月26日，因指证证据发生变化，现有证据无法证实其涉案嫌疑， 公安机关依法解除取保候审。但作为上市公司董事长，邢雅江未在第一时间将这一影响投资者决策的重 大事项报告公司并对外披露，直至2024年8月24日才通过公司公告公开相关信息，违规延迟披露时长超 四个月。 值得关注的是，在监管调查及听证过程中，邢雅江及其代理人提出两项申辩理由：一是声称"客观上无 法确认自身法律状态的变化"，不存在主观过错；二是认为处罚过重， ...

Core Viewpoint - Jinhua Enterprises (Group) Co., Ltd. faces regulatory scrutiny due to its chairman's failure to disclose information related to his criminal investigation, resulting in a fine and warning from the Shaanxi Securities Regulatory Bureau [2] Company Summary - Jinhua Enterprises is a pharmaceutical industrial company engaged in the research, production, and sales of drugs, with a product line that includes chemical drugs, traditional Chinese medicine, raw materials, and health products [2] - The company reported a total operating revenue of 384 million yuan for the first three quarters, representing a year-on-year decline of 8.36% [2] - Net profit for the same period was 34.48 million yuan, showing a year-on-year increase of 12.06% [2] Regulatory Actions - Chairman Xing Yajiang received an administrative penalty decision from the Shaanxi Regulatory Bureau for failing to timely disclose information regarding his criminal investigation [2] - The penalty includes a warning and a fine of 3.5 million yuan [2] - A hearing was held on July 25, where Xing and his representatives presented their defense, which was ultimately not accepted upon review [2]

Core Viewpoint - Jin Hua Enterprise (Group) Co., Ltd. faced regulatory penalties due to Chairman Xing Yajiang's failure to timely disclose personal legal matters, resulting in a warning and a fine of 3.5 million yuan from the Shaanxi Securities Regulatory Bureau [2][4]. Group 1: Regulatory Issues - Xing Yajiang was placed under residential surveillance by the Xi'an Public Security Bureau on April 23, 2024, but was released on July 26, 2024, due to insufficient evidence [4]. - The company disclosed the legal matter only on August 24, 2024, which was deemed a violation of information disclosure regulations by the Shaanxi Securities Regulatory Bureau [4]. - Xing's defense during the hearing, claiming uncertainty about his legal status and arguing that the punishment was excessive, was rejected due to lack of supporting evidence [4]. Group 2: Previous Violations - Since the beginning of 2024, Xing Yajiang has been involved in multiple regulatory violations, including inaccurate disclosures regarding Jin Hua's 2023 performance forecast, which led to criticism from the Shanghai Stock Exchange and a warning letter from the Shaanxi Securities Regulatory Bureau [5]. Group 3: Company Overview - Jin Hua's main business includes the research, production, and sales of pharmaceuticals, with a product line that encompasses chemical drugs, traditional Chinese medicine, raw materials, and health products [5]. - The company offers over a hundred varieties of dosage forms, including tablets, capsules, and granules, categorized into series such as orthopedic, immunological, pediatric, and general medicines [5].

Group 1 - The Chinese medicine sector experienced a slight increase of 0.45% on December 18, with Yibai Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3876.37, up 0.16%, while the Shenzhen Component Index closed at 13053.98, down 1.29% [1] - Key stocks in the Chinese medicine sector showed varied performance, with Yibai Pharmaceutical closing at 4.29, up 5.67%, and other notable gainers including Jinhua Co. and Xinda Pharmaceutical [1] Group 2 - The Chinese medicine sector saw a net outflow of 362 million yuan from major funds, while retail investors contributed a net inflow of 384 million yuan [2] - Among the stocks, *ST Changyao experienced the largest decline, down 6.21% to 1.51, while Zhongsheng Pharmaceutical and Te Yi Pharmaceutical also faced losses [2] - The trading volume and turnover for various stocks in the sector varied significantly, with Zhongsheng Pharmaceutical recording a turnover of 910 million yuan despite a decline [2] Group 3 - Major funds showed a net inflow in stocks like Pianzi Shou and Lingrui Pharmaceutical, while retail investors had mixed results across different stocks [3] - The net inflow for Pianzi Shou was 22.60 million yuan, while other stocks like Guizhou Bailing and Taiji Group also saw notable fund movements [3] - The overall trend indicates a divergence in fund flows, with some stocks attracting significant retail interest despite overall sector outflows [3]